LifeView
Preimplantation genetic testing for polygenic risk assessment
Platform · OtherCompany source
Company profile
About Genomic Prediction
Genomic Prediction is a precision medicine company specializing in advanced genetic testing and polygenic risk assessment for reproductive health. The company develops and offers preimplantation genetic testing services that utilize polygenic risk scores to evaluate embryos during in vitro fertilization (IVF) procedures. Their technology analyzes multiple genetic variants simultaneously to assess risk for complex conditions and traits, going beyond traditional single-gene disorder screening. Genomic Prediction's services are designed to provide prospective parents and fertility clinics with comprehensive genetic information to support informed decision-making during the embryo selection process. The company operates at the intersection of genomics, artificial intelligence, and reproductive medicine, applying computational methods to interpret genetic data and predict health outcomes. Their approach represents an evolution in preimplantation genetic testing, incorporating polygenic risk assessment alongside traditional genetic screening methods to provide a more complete picture of embryo health potential.
Company description Genomic Prediction official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Genomic Prediction?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- complex genetic conditions
- polygenic diseases
- reproductive health conditions
Who it serves
- fertility centers
- IVF clinics
- reproductive medicine providers
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Highly efficient base editing at PCSK9 and normal human embryo development.Nature · Sep 9, 2026
Asymmetric attrition and secondary chromosome destabilization after double-strand breaks in human embryonic development.Nature communications · Jun 3, 2026
Accuracy of direct mutation testing by TaqMan quantitative polymerase chain reaction for preimplantation genetic diagnosis of recurrent de novo mutations.Fertility and sterility · Apr 1, 2026
Population-specific polygenic risk scores for people of Han Chinese ancestry.Nature · Dec 1, 2025
Blastocyst segmental aneuploidy breakpoints are highly correlated with human genome fragile sites.Human reproduction (Oxford, England) · Oct 1, 2025
Routine detection of consanguinity through preimplantation genetic testing in human embryos.Reproductive biomedicine online · May 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Genomic Prediction
Recent articles published on Genomic Prediction's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.